×
Bright Minds Biosciences Receivables 2022-2024 | DRUG
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Bright Minds Biosciences receivables from 2022 to 2024. Receivables can be defined as the total amount of collectibles for a company
View More
Bright Minds Biosciences Receivables 2022-2024 | DRUG
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Bright Minds Biosciences receivables from 2022 to 2024. Receivables can be defined as the total amount of collectibles for a company
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$173B
Vertex Pharmaceuticals (VRTX)
$129.4B
Gilead Sciences (GILD)
$121.9B
Bristol Myers Squibb (BMY)
$111B
CSL (CSLLY)
$91.9B
Regeneron Pharmaceuticals (REGN)
$90.6B
GSK (GSK)
$76B
Argenex SE (ARGX)
$35.4B
Alnylam Pharmaceuticals (ALNY)
$35.1B
BioNTech SE (BNTX)
$25.7B
Biogen (BIIB)
$25.3B
Illumina (ILMN)
$24.6B
BeiGene (BGNE)
$20.1B
Moderna (MRNA)
$19.3B
Incyte (INCY)
$15.9B
Genmab (GMAB)
$15.3B
Insmed (INSM)
$12.8B
Vaxcyte (PCVX)
$12.8B
BioMarin Pharmaceutical (BMRN)
$12.8B
Bio-Techne Corp (TECH)
$12.1B
Sarepta Therapeutics (SRPT)
$11.5B
Exelixis (EXEL)
$10.2B
QIAGEN (QGEN)
$10.1B
Revolution Medicines (RVMD)
$9.9B
Exact Sciences (EXAS)
$9.9B
Intra-Cellular Therapies (ITCI)
$9.6B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$8.7B
Repligen (RGEN)
$8.1B
Ascendis Pharma (ASND)
$7.7B